14.82
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 4.6%Should You Sell? - MarketBeat
Woodline Partners LP Buys 112,128 Shares of Spyre Therapeutics, Inc. $SYRE - MarketBeat
Can Spyre Therapeutics Inc maintain sales growthJuly 2025 Recap & Community Verified Swing Trade Signals - خودرو بانک
What does recent volatility data suggest for Spyre Therapeutics Inc.Market Movement Recap & AI Enhanced Trading Signals - newser.com
Published on: 2025-09-16 12:08:18 - newser.com
US Market Recap: Is Spyre Therapeutics Inc stock good for income investors2025 AllTime Highs & Weekly High Return Stock Opportunities - خودرو بانک
Spyre Therapeutics (SYRE): Analyst Reiterates Buy Rating | SYRE Stock News - GuruFocus
Can you recover from losses in Spyre Therapeutics Inc.Quarterly Profit Review & Capital Efficiency Focused Strategies - newser.com
Support Test: Is Spyre Therapeutics Inc benefiting from interest rate changesQuarterly Portfolio Report & Fast Moving Stock Trade Plans - خودرو بانک
Tools to monitor Spyre Therapeutics Inc. recovery probabilityEarnings Recap Report & Entry Point Confirmation Alerts - newser.com
Growth Recap: Is Spyre Therapeutics Inc stock good for income investorsJuly 2025 Selloffs & Free Weekly Chart Analysis and Trade Guides - خودرو بانک
Value Recap: Is Spyre Therapeutics Inc a top pick in the sectorJuly 2025 Trends & Weekly Consistent Profit Watchlists - خودرو بانک
Is Spyre Therapeutics Inc. stock bottoming out2025 Bull vs Bear & Smart Money Movement Tracker - newser.com
History Review: What are Spyre Therapeutics Inc.’s growth leversJuly 2025 Movers & AI Enhanced Execution Alerts - خودرو بانک
What Fibonacci levels say about Spyre Therapeutics Inc. reboundBull Run & Fast Exit/Entry Strategy Plans - newser.com
Spyre Therapeutics (SYRE) Doses First Patient In Promising SPY072 Phase 2 Trial - Yahoo Finance
Spyre Therapeutics doses first patient in phase 2 rheumatic disease trial - Investing.com
Spyre Flat on Test Result - Baystreet.ca
Spyre Therapeutics doses first patient in phase 2 rheumatic disease trial By Investing.com - Investing.com South Africa
Spyre doses first patient in phase 2 SKYWAY trial of SPY072, first anti-TL1A antibody for rheumatic diseases - MarketScreener
First-Ever Anti-TL1A Drug for 3M+ Rheumatic Patients: Spyre's SPY072 Enters Phase 2 Trial - Stock Titan
Detecting support and resistance levels for Spyre Therapeutics Inc.July 2025 Gainers & Technical Pattern Based Buy Signals - newser.com
Chart overlay techniques for tracking Spyre Therapeutics Inc.Entry Point & High Conviction Buy Zone Picks - newser.com
Automated trading signals detected on Spyre Therapeutics Inc.2025 Institutional Moves & Weekly Chart Analysis and Guides - newser.com
Does Spyre Therapeutics Inc. qualify in momentum factor screeningGold Moves & Risk Controlled Stock Alerts - newser.com
How to use a screener to detect Spyre Therapeutics Inc. breakoutsJuly 2025 Drop Watch & AI Powered Market Entry Strategies - newser.com
We're Hopeful That Spyre Therapeutics (NASDAQ:SYRE) Will Use Its Cash Wisely - 富途牛牛
Order flow analysis tools used on Spyre Therapeutics Inc.2025 AllTime Highs & Daily Volume Surge Trade Alerts - Newser
What’s next for Spyre Therapeutics Inc. stock price2025 Technical Overview & Safe Entry Trade Signal Reports - Newser
Does Spyre Therapeutics Inc. fit your quant trading model2025 Market Outlook & Momentum Based Trading Signals - Newser
Smart tools for monitoring Spyre Therapeutics Inc.’s price action2025 Trade Ideas & Consistent Growth Equity Picks - Newser
Combining price and volume data for Spyre Therapeutics Inc.Market Performance Recap & AI Driven Stock Price Forecasts - Newser
Wall Street Zen Upgrades Spyre Therapeutics (NASDAQ:SYRE) to "Hold" - MarketBeat
Exit strategy if you’re trapped in Spyre Therapeutics Inc.Dollar Strength & Consistent Return Investment Signals - Newser
Has Spyre Therapeutics Inc. formed a bullish divergenceWeekly Earnings Recap & Low Volatility Stock Suggestions - Newser
Technical signs of recovery in Spyre Therapeutics Inc.July 2025 Decliners & Weekly Market Pulse Updates - Newser
Spyre Therapeutics Inc. stock momentum explained2025 Historical Comparison & Growth Focused Investment Plans - Newser
Can swing trading help recover from Spyre Therapeutics Inc. losses2025 Analyst Calls & Consistent Profit Trade Alerts - Newser
Real time pattern detection on Spyre Therapeutics Inc. stockQuarterly Trade Review & Daily Risk Controlled Trade Plans - Newser
What high frequency data says about Spyre Therapeutics Inc.Market Trend Review & Risk Managed Investment Strategies - Newser
Should you hold or exit Spyre Therapeutics Inc. now2025 Market Overview & Safe Entry Point Identification - Newser
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):